Search

Displaying results 4031 - 4040 of 9670 in total
  1. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    It may be found in cosmetics and personal care products as an emollient or skin conditioning agent. … According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance.

  2. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

  3. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … [A230088,A230593] In the past, management strategies for this disorder involved symptomatic and supportive treatment,[L32163] though efforts were made to develop a suitable exogenous replacement for the

  4. Drug

    Quaternium-24

    go.drugbank.com/drugs/DB13969
    Approved

    Mixtures: Sanitizing Wet Wipes
  5. Drug

    Colletotrichum coccodes

    go.drugbank.com/drugs/DB10824
    Approved

    Colletotrichum coccodes is a fungus which can provoke allergic reactions. Colletotrichum coccodes extract is used in allergenic testing.

    Mixtures: Treatment Set TS128871
  6. Drug

    SW033291

    go.drugbank.com/drugs/DB32765
    Experimental

    [A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]

  7. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    It has been investigated for the treatment of hodgkin’s lymphoma.

  8. Drug

    Chromic citrate

    go.drugbank.com/drugs/DB14526
    Experimental

  9. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. … It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe.

  10. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.